Dermata Therapeutics (DRMA) Common Equity (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Common Equity of $6.4 million for Q1 2026, down 12.17% year-over-year from $7.3 million in Q1 2025, and up 3.05% quarter-over-quarter from $6.2 million in Q4 2025.
Dermata Therapeutics (DRMA) Common Equity (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Common Equity fell 12.17% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (down 12.17% YoY), while the FY2025 annual figure was $6.2 million, up 298.66% from the prior year.
- Common Equity for Q1 2026 stood at $6.4 million, up from $6.2 million in the prior quarter.
- The five-year high for Common Equity was $9.7 million in Q2 2022, with the low at $1.6 million in Q4 2024.
- The 5-year median for Common Equity is $6.4 million (2023), against an average of $6.0 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 2009.83% in 2022, then tumbled 75.44% in 2024.
- Dermata Therapeutics' Common Equity stood at $6.0 million in 2022, then grew by 5.53% to $6.4 million in 2023, then sank by 75.44% to $1.6 million in 2024, then jumped by 298.66% to $6.2 million in 2025, then climbed by 3.05% to $6.4 million in 2026.
- Business Quant data shows DRMA's Common Equity at $6.4 million in Q1 2026, $6.2 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | 6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 6.22 Mn |
| Sep 30, 2025 | 3.96 Mn |
| Jun 30, 2025 | 5.61 Mn |
| Mar 31, 2025 | 7.30 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 6.36 Mn |
| Sep 30, 2023 | 6.41 Mn |
| Jun 30, 2023 | 8.03 Mn |
| Mar 31, 2023 | 8.09 Mn |
| Dec 31, 2022 | 6.02 Mn |
| Sep 30, 2022 | 7.47 Mn |
| Jun 30, 2022 | 9.66 Mn |
| Mar 31, 2022 | 7.85 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Sep 30, 2021 | 12.49 Mn |
| Jun 30, 2021 | -505,802.00 |